Table 1

 Characteristics of randomised trials comparing drug eluting stents with bare metal stents

StudyDiabetes mellitusMean age at baseline (years)Women (%)Hypertension (%)Dyslipidaemia (%)Smoking (%)Mean follow up (months)
YesNoAngiographicClinical
C-SIRIUS, Canadian sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; DIABETES, diabetes and sirolimus eluting stent trial; E-SIRIUS, European sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions; NA, not available; RAVEL, randomised study with the sirolimus eluting velocity balloon expandable stent; SES-SMART, randomised comparison of a sirolimus eluting stent and a standard stent in the prevention of restenosis in small coronary arteries; SIRIUS, sirolimus coated balloon expandable stent in the treatment of patients with de novo coronary artery lesions.
Sirolimus eluting stents
SIRIUS (2003)427977862.329.068.074.020.089
E-SIRIUS (2003)18127162.329.364.074.033.089
C-SIRIUS (2004)3247660.531.052.085.037.089
DIABETES (2005)3016066.637.566.361.347.599
RAVEL (2002)24419460.724.061.040.030.0612
SES-SMART (2004)86419363.628.464.763.016.388
Paclitaxel eluting stents
TAXUS I (2003)5114964.911.463.980.350.8612
TAXUS II (2003)6, 32, 337645360.124.461.576.624.8624
TAXUS IV (2004)7, 2931899662.527.969.865.321.8924
TAXUS VI (2005)318935762.623.757.871.9NA912